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Abstract
Background: Mannose-binding lectin (MBL), a pattern recognition innate immune molecule, inhibits influenza A
virus infection in vitro. MBL deficiency due to gene polymorphism in humans has been associated with infection
susceptibility. These clinical observations were confirmed by animal model studies, in which mice genetically
lacking MBL were susceptible to certain pathogens, including herpes simplex virus 2.
Results: We demonstrate that MBL is present in the lung of naïve healthy wild type (WT) mice and that MBL null
mice are more susceptible to IAV infection. Administration of recombinant human MBL (rhMBL) reverses the
infection phenotype, confirming that the infection susceptibility is MBL-mediated. The anti-viral mechanisms of
MBL include activation of the lectin complement pathway and coagulation, requiring serum factors. White blood
cells (WBCs) in the lung increase in WT mice compared with MBL null mice on day 1 post-infection. In contrast,
apoptotic macrophages (MFs) are two-fold higher in the lung of MBL null mice compared with WT mice.
Furthermore, MBL deficient macrophages appear to be susceptible to apoptosis in vitro. Lastly, soluble factors,
which are associated with lung injury, are increased in the lungs of MBL null mice during IAV infection. These
results suggest that MBL plays a key role against IAV infection.
Conclusion: MBL plays a key role in clearing IAV and maintaining lung homeostasis. In addition, our findings also
suggest that MBL deficiency maybe a risk factor in IAV infection and MBL may be a useful adjunctive therapy for
IAV infection.
Background
IAV is an enveloped RNA virus with a capsule that con-
tains neuraminidase and hemagglutinin, both of which
are glycosylated [1]. One of the characteristics of IAV
infection is the production of a large number of apopto-
tic cells [2]. IAV infection, a very common infection, is
estimated to cause 20 fatalities and 52 hospitalizations
per 100,000 persons in the United States alone [3].
The first line of host defense mechanism is the innate
immunity. The innate immune system utilizes innate
immune cells, including phagocytes, such as macrophages
(MFs) and polymorphonuclear neutrophils (PMNs) [4]. In
the innate immune system, pathogens are identified by
pattern recognition molecules, including lectins [4]. One
such lectins is MBL, a serum protein, which is primarily
synthesized in the liver [5]. MBL was identified to be a b-
inhibitor that neutralized IAV in a calcium-dependent
fashion [6,7]. A genetic basis for MBL deficiency correlat-
ing with infection susceptibility was established in the
1990s [8]. Many in vitro studies have described MBL’s
anti-viral functions, including viral aggregation, inhibition
of viral hemagglutination and opsonization of virus
[7,9,10]. MBL also activates complement via the lectin
pathway, which requires MBL-associated serine proteases
(MASPs) [11]. The lectin complement pathway, therefore,
does not require antibody, which is not immediately avail-
able since the adaptive immune system has not had time
to respond at the moment of initial viral infection.
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A complex of MBL and MASP also initiates coagulation
via thrombin-like activity [12,13]. Coagulation is a primi-
tive yet an effective host defense mechanism. For example,
tachylectins in horseshoe crab hemolymph provide innate
immune protection by clotting lipopolysaccharide and b-
glucan [14] (PAMPs of Gram negative bacteria and fungi,
respectively).
MBL belongs to the collectin family that is character-
ized structurally by a type II collagen-like domain at the
C-terminus followed by a neck region and a carbohy-
drate recognition domain (CRD) at the N-terminus [15].
The collectin family also includes lung surfactant pro-
tein (SP)-A and SP-D [15]. These surfactant proteins
provide lung protection and are constitutively present in
lungs, where initial IAV infection typically takes place
[16]. Mice lacking SP-A or SP-D have increased suscept-
ibility to IAV infection [17]. In contrast, MBL has not
been detected in healthy lungs although MBL levels
increase in the lung following infection [18] and a mes-
senger RNA for MBL has been detected at very low
levels in the lung [5]. Nonetheless, MBL deficiency has
been associated with lung disease, including non-cystic
fibrosis [19-21].
Humans have a single MBL protein derived from a
single gene while mice have two proteins, termed MBL-
A and MBL-C that are transcribed from two indepen-
dent genes located on different chromosomes [15].
Human MBL is genetically homologous to MBL-C
although MBL-A is functionally similar to human MBL
in that these two proteins are both acute phase proteins
while mouse MBL-C is constitutively expressed [15].
The human MBL gene has multiple polymorphisms,
some of which produce low levels of MBL and dysfunc-
tional MBL and have been clinically associated with sus-
ceptibility to infection [15]. The clinical observations
were confirmed in animal models of infection using
mice that lack both MBL-A and MBL-C and which are
therefore null for MBL[22].
In this study, we investigated whether MBL plays a
role against IAV infection by comparing MBL null and
WT mice and further analyzed anti-viral mechanisms
of MBL.
Methods
MBL binding assay
This assay was performed using previously described
methods with a minor modification [23]. Briefly, 96 well
plates were coated with viruses (1000-1 HA titer/well) in
50 μl of a bicarbonate buffer, pH 9.5 and blocked and
then various concentrations of recombinant human
MBL (rhMBL) in 50 μl was added and incubated at
room temperature. After washing, virus-bound MBL
was detected by mouse anti-hMBL monoclonal Ab
(mAb) 131-1 (State Serum Institute, Denmark) followed
by alkaline-phosphatase conjugated goat anti-mouse IgG
Ab and pNTP substrate. The reactions were read at 415
nm using a SpectraMax M5 (Molecular Devices, CA).
For mannan inhibition experiments, virus coated wells
were incubated with various concentrations of mannan
together with rhMBL at 2 μg/ml. Binding was expressed
as the OD 415 nm reading and mannan binding inhibi-
tion was calculated as % Inhibition = [(OD 415 without
mannan) - (OD 415 nm with mannan))/(OD 415 nm
without mannan)] × 100.
Virus neutralizing assay in vitro
Test samples included rhMBL, purified MBL-A, purified
MBL-C, and serum from WT mice and various mice
lacking MBL-A, MBL-C or both. Purified mouse MBLs,
rhMBL and sera were used at the indicated concentra-
tions. The assay was performed as previously described
[24]. Briefly, viruses were pre-incubated with test sam-
ples, washed and then incubated with Madin-Darby
canine kidney (MDCK) cells. Infection was assayed by
FITC-conjugated anti-IAV antibody (Ab)(Millipore,
MA). Fluorescent foci were counted. Virus neutralizing
activity (%) was calculated by the formula: (fluorescent
foci counts (FFC) in saline - FFC in test sample) × 100/
FFC in saline control.
Assays of lectin complement activity and thrombin-like
activity
The lectin pathway assay was performed with a minor
modification of a previously described method [23].
Briefly, 96 well plates were coated with IAV in bicar-
bonate buffer, pH 9.5. After washing and blocking with
BSA, wells were incubated with 1% serum diluted in a
binding buffer, 10 mM Tris, pH 7.4, 10 mM CaCl2, 1
M NaCl and incubated at room temperature. After
washing, the wells were incubated with human C4 at
37°C. After washing again, the wells were incubated
with rabbit anti-hC4c Ab followed by alkaline phos-
phatase-conjugated goat anti-rabbit IgG Ab and then
with pNTP. The plates were read at OD 415 nm.
Pooled human serum with a known MBL concentra-
tion (State Serum Institute, Denmark), which was
defined as having 1,000 U/ml of C4 deposition activity,
was used to generate a standard curve on mannan-
coated wells in order to obtain relative C4 deposition
activity.
Thrombin-like activity was assayed using 384 well
plates, which were coated with IAV as above. After
washing, the wells were incubated with 10% serum
diluted in the binding buffer. After washing again, wells
were incubated with rhodamine 110-thrombin substrate
(R22124, Invitrogen, CA) in TBS-CaCl2 and read using
500 nm excitation/520 nm emission using the Spectra-
Max M5.
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Mice
MBL null mice were generated and fully backcrossed
onto C57Black/6J [23,25]. Mice were used at ages
between 6 and 10 weeks old. Gender and age were
matched in each experiment. All animal experiments
were performed under a protocol approved by the Sub-
committee on Research Animal Care at Massachusetts
General Hospital, Boston, MA.
MBL detection in bronchoalveolar lavage fluid (BALF)
Mice were euthanized and a 22G catheter was inserted
into the bronchi and secured with a nylon suture (6-0,
Ethicon). BALF was collected using 3 lavages with 0.5
ml of PBS-EDTA and combined (Recovered BALF was
approximately 1 ml). After centrifugation, four fifths of
the BALF was mixed with TBS, supplemented with 10
mM CaCl2 and 1 M NaCl (binding buffer) and incu-
bated with 20 μl of mannose agarose beads (Sigma, 1:1
in the binding buffer) over night on an end-over-end
rotator at 4°C. The mannose agarose beads were col-
lected and washed with TBS. The washed beads were
subjected to SDS-PAGE using a 12% polyacrylamide gel
under reducing conditions. Fractionated proteins were
transferred to a nylon membrane (Immobilon P, Milli-
pore) and Western blot analysis was performed using
rabbit anti-human MBL Ab [26]. 1 μg of purified native
mouse serum MBL was used as a positive control. The
reaction was visualized using Western blue (Promega,
WI). MBL bands were analyzed using a ChemiDoc scan-
ner (Bio-Rad, CA) and the software provided with the
ChemiDoc. MBL amounts were calculated as relative %
volume of 100%, which combined all MBL bands in
WT, MBL-A null, MBL-C null and the purified native
mouse serum MBL.
MBL ELISA of the BALF was performed using pre-
viously described methods with minor modifications
[27]. Briefly, 96 well plates were coated with mannan.
Following washing and blocking, the wells were
incubated with diluted BALF, 50% in the binding buffer.
Bound MBLs were detected by rat monoclonal antibo-
dies against MBL-A or MBL-C followed by alkaline-
phosphatase conjugated anti-rat Ab and pNTP substrate.
The reactions were read at 415 nm using the Spectra-
Max M5.
Viral infection-induced cell death assay
Peritoneal resident MFs were prepared by lavage of the
peritoneal cavity with 5 ml PBS, performed twice for
each animal and pooled. Lavaged peritoneal cells were
washed and plated at 4 × 104 cells/well in 50 μl of cul-
ture media (RPMI1640, supplemented with 10% FBS).
After incubation for 1 hr at 37°C, 5% CO2, wells were
washed with PBS to remove non-adherent (non-MF)
cells. Adherent cells (MFs) were further incubated with
influenza A virus (5 × 106 ffc/40 μl/well in RPMI1640)
at 37°C in a CO2 incubator for 1 hr. 60 μl of culture
media was added and incubated over night at 37°C in a
CO2 incubator. Cell survival was assayed using WST2
reagent (Dojindo Molecular technologies, Inc., MD),
according to the manufacturer’s instruction. The WST2
reaction was read at OD 450 nm using the Spectramax
M5. Cell death (%) was calculated by the formula: [OD
450 nm of WT MFs alone - OD 450 nm of test groups)
× 100)/OD 450 nm of WT MFs alone].
In vivo IAV infection experiment
IAV, Philippine 82 H3N2 (Phil82) and Phil82BS, which
lacks one glycosylation site compared to Phil 82, were
prepared as described previously [28]. Mice were
anesthetized with avertin as described previously and
were intranasally inoculated with 5 × 106 fluorescent
foci counts (FFC) of IAV in 50 μl PBS. Bronchoalveolar
lavage fluid (BALF), BAL cells and lung homogenates
were prepared on days 1, 4 and 7 following virus infec-
tion as described previously with minor modifications
[29]. BALF aliquots were stored in the -80°C freezer for
use in the experiments on soluble factors. BAL cells
were spun on to individual glass slides using a Cytopro
centrifuge (Wescor Inc., UT) and stained using Diff-
Quick (Sigma, MO) for differential cell counts under a
microscope (Nikon 800). Apoptotic cells were identified
by positive staining for Annexin V and counterstaining
with Hoechst stain for cell type identification. A total of
100 ~ 120 cells in 3 ~ 5 fields per sample were counted
in a blinded manner, in which samples were labeled
with only mouse identification numbers.
Virus titers were determined using a MDCK infection
assay as previously described [24]. Reconstitution experi-
ments using MBL null mice and rhMBL were performed
by intraperitoneal injection of 75 μg rhMBL (a gift from
Enzon, USA) at one hr prior to viral infection, as pre-
viously described [23]. The 75 μg dose was calculated
based on the lectin complement activation activity of
rhMBL and purified mouse MBLs [23]. In addition,
restored lectin pathway activity in MBL null mice was
similar to that in WT mice [23].
Assay of soluble molecules in BALF of IAV-infected mice
BALF on day 1 post-viral infection was collected as
described above. Three BALF aliquots were pooled and
were analyzed for 62 soluble molecules in duplicate
using a cytokine antibody array (RayBiotech Inc., GA),
according to the manufacturer’s instructions and as pre-
viously described [25]. Chemiluminescence reaction in
membranes was simultaneously captured by the Chemi-
Doc (Bio-Rad, Hercules, CA) and relative chemilumines-
cent intensity (arbitrary units) was obtained using the
software provided with the ChemiDoc. Results were
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expressed as the fold-increase in WT relative to MBL
null mice or vise versa. 2-fold increase was defined as
positive.
Statistical analysis
All data were analyzed by ANOVA or Wilcoxon/Krus-
kal-Wallis tests for non-parametric data using JMP soft-
ware (SAS institute Inc., NC). p values less than 0.05
were considered to be significant.
Results
Human and murine MBL binds and neutralizes influenza
A viruses
We chose Phil82 and Phil82 BS strains because the lat-
ter lacks one glycosylation site from the parent Phil82
strain [28], thus it was hypothesized that MBL should
bind Phil82 more efficiently compared with Phil82BS.
As expected, MBL bound to Phil82 significantly greater
than Phil82BS (Figure 1A). Exogenous mannan abol-
ished MBL-binding more efficiently against Phil82 com-
pared to Phil82BS (Figure 1B), suggesting that the virus
binding was mediated through the CRD of MBL. Virus
neutralizing activity was correlated with IAV-MBL bind-
ing activity (Figure 1C). This result supports the pre-
vious finding that rhMBL alone is able to neutralize IAV
[10]. These results demonstrate that MBL by itself is
capable of inhibiting IAV infection and that the activity
is MBL-binding dependent.
Next, we assessed the viral neutralizing activity of
murine MBL-A and MBL-C. Purified MBL-C demon-
strated greater viral neutralizing activity against Phil82
than purified native MBL-A (Figures 2A and 2B).
Further experiment showed no inhibitory effect of the
purified MBL-A even at 400 ng/ml. The concentration
used in this study, 100 ng/ml, is comparable to the MBL
concentration that was detected in BALF following viral
infection in mice [18]. Purified MBL-C was also able to
inhibit Phil82BS IAV (Figure 2B).
We subsequently tested the effect of sera from various
mouse strains in a similar manner. MBL-A deficient
serum (= MBL-C sufficient) and MBL-C deficient serum
(= MBL-A sufficient) demonstrated similar viral neutra-
lizing activity to both viral strains (Figures 2C and 2D).
The activity was observed at 1% and 10% serum but not
at 0.1% serum. Thus, despite the undetectable direct
viral neutralizing activity of MBL-A against Phil82BS
(Figure 2B) the serum containing MBL-A (= MBL-C
null serum) demonstrated IAV neutralizing activity. The
serum concentration of MBL-A and MBL-C is approxi-
mately 10 and 25 μg/ml, respectively, as we previously
assayed in these mice (57). Therefore, the concentration
of MBL-A and MBL-C in 1% serum is 100 ng/ml and
250 ng/ml, respectively, which are comparable to those
tested for purified MBL proteins.
Strikingly, serum lacking both MBL (MBL null) lost
more than 50% of the viral neutralizing activity com-
pared with WT serum and serum lacking MBL-A or
MBL-C against both viral strains (Figures 2C and 2D).
Taken together, these data suggested that IAV neutraliz-
ing activity was MBL-dependent and that serum factors
augmented MBL’s viral neutralizing activity.
MBL activates complement and a thrombin-like activity
on IAV
Lectins activate complement and coagulation as an anti-
microbial mechanism [12-14]. Therefore, we investigated
MBL-mediated activation of complement and a throm-
bin-like activity against IAV. The lectin complement
pathway activity was comparable between MBL-C null
(MBL-A sufficient) and WT mouse serum while the
activity was about one-half in MBL-A null serum (MBL-
C sufficient) and was negligible in MBL null serum
Figure 1 Recombinant human MBL (rhMBL) binds and neutralizes
IAV. Closed circles and open circles represent Phil82 and Phil82BS
strain, respectively. A, rhMBL binding to IAV. B, Mannan inhibition of
rhMBL-IAV binding. Both assays were performed in triplicates and
expressed as mean ± SD. C, Neutralizing activity of rhMBL. Assay was
performed in duplicates and repeated twice. All data was combined
and expressed as mean ± SE. *, p < 0.05.
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Figure 2 Murine MBL-A and MBL-C. A and B, Viral neutralizing activity of purified native MBL-A and MBL-C against Phil82 (A) and Phil82BS (B).
C and D, Viral neutralizing activity of mouse serum against Phil82 (C) and Phil82BS (D). Experiments were repeated at least twice. All data were
combined and expressed as mean ± SE. *, p < 0.05. E, Lectin complement pathway activation activity. C4 deposition on virus was expressed as
U/ml. Assays were performed in duplicate. WT, wild type; A/C, MBL-A/MBL-C null (= MBL null), A, MBL-A null, C, MBL-C null. Representative data
of three experiments is shown. Assays were performed in triplicate and expressed as mean ± SE. *, p < 0.0001 against WT and MBL-C null. F,
Thrombin-like activity. Same serum source as in Figure 2E. Assays were performed in triplicate and expressed as mean ± SE. *, p < 0.0001 against
MBL null and MBL-C null. G, Presence of MBL in lungs. Western blot analysis of affinity purified MBL from BALF. mMBL, purified native serum
murine MBL (1 μg) as a positive control. Each lane represents individual mouse. % volume for detected MBL bands was calculated as described
in the materials and methods.
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(Figure 2E). These results support our previous findings
that purified native MBL-A activated the lectin comple-
ment pathway more effectively than purified native
MBL-C on a mannan-coated surface [23].
In contrast, thrombin-like activity was observed in
WT and MBL-A null mouse serum at comparable levels
while it was only one-tenth in MBL-C null mouse
serum and was undetectable in MBL null mouse serum
(Figure 2F). These data suggest that MBL-A and MBL-C
preferentially activate the lectin complement pathway
and thrombin-like activity, respectively. These MBL-
mediated activities were results of activated MASPs,
which can bind MBL [11].
Presence of MBL in the lung
In order to determine presence of MBL in the lung,
D-mannose agarose beads, to which MBL has high affi-
nity, were incubated with BALF collected from each
mouse and were then subjected to Western blot analy-
sis. Two bands were observed. One of them was imme-
diately above mMBL bands and was absent in the
purified mMBL (mMBL, 35 kD). Therefore, these bands
were concluded to be due to non-specific reaction of
the rabbit anti-human MBL polyclonal Ab. Protein
bands, corresponding to purified mMBL, were detected
in BALF of WT mice whereas they were undetectable in
MBL null mice (Figure 2G). Relative % volume of the
MBL band in WT mouse BALF was 24 and was close to
29 of mMBL 1 μg (Figure 2G). As expected, the relative
%volume of MBL bands in MBL-A or MBL-C single
null mouse BALF was 12 and 10, respectively, therefore
these were roughly 50% of MBL in WT mouse BALF,
which contains both MBL-A and MBL-C (Figure 2G).
These Western blot analyses demonstrated that approxi-
mately 1 μg of combined MBL-A and MBL-C was pre-
sent in the resting healthy lung of WT mice. However,
ELISA using aliquots of the same BALF sample was
unable to detect MBL. This may be due to the ELISA
being insufficiently sensitive, or possibly related to other
factors in the BALF. The finding of MBL in the resting
lung supports our idea that MBL has a role in the lung
in preventing IAV.
Increased viral infection in MBL null mice
To test our hypothesis that MBL prevents IAV infection,
we subjected MBL null and WT mice to primary lung
infection with IAV. For in vivo study, we chose Phil82
strain because both Phil82 and Phil82BS strains were
similarly neutralized by MBL containing mouse sera
despite the difference in viral-MBL binding capacity
(Figures 2A, B, C, and 2D). Thus, we concluded that in
vivo responses against Phil82 strain would be similar to
those against Phil82BS. Virus was not detected in lungs
following intranasal inoculation of PBS in both WT and
MBL null mice (data not shown). In contrast, viral titers
in lungs of MBL null mice were significantly higher com-
pared with WT mice on day 1, after which they decreased
to low to undetectable at later time points, days 4 and 7
in both MBL null and WT mice (Figure 3A). These
results demonstrate that MBL null mice have an
increased susceptibility to IAV infection, suggesting
that lack of MBL reduces the host defense against IAV in
the lung.
To further explore these findings, MBL null mice were
injected (i.p.) with 75 μg of rhMBL one hr prior to viral
inoculation [23]. Virus titers in lungs of reconstituted
MBL null mice were comparable to that of WT mice
(Figure 3B). These results confirmed that the increased
susceptibility to IAV infection in MBL null mice was
due to the lack of MBL and that MBL deficiency could
be corrected by administration of rhMBL.
Increased total WBCs in BAL of WT mice
Next, we examined BAL cells in the infected lungs.
Total WBCs in BAL of WT mice were significantly
increased compared with MBL null mice on day 1 while
they were similar in both strains of mice at the later
time points (Figure 4A). Of these WBCs, the PMN
population was significantly increased in both WT and
MBL null mice at day 1 compared with the later time
Figure 3 Increased virus titers in the lungs of MBL null mice. A,
Virus titers in lung homogenates following IAV infection were
assayed on days 1, 4 and 7. Three mice were used for each group
at each time point. Virus titers were expressed as FFC/lung (g) ± SE.
*, p < 0.005. B, Administration of rhMBL rescues susceptible
phenotype of MBL null mice. MBL null mice were reconstituted with
rhMBL or PBS as a control and virus titer was determined in lung
homogenates at 24 hr after virus inoculation. Mice used were 7, 5
and 4 for MBL null, MBL null + rhMBL and WT mice, respectively.
Virus titers were expressed as FFC/lung (g) ± SE. *, p < 0.005.
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points. Furthermore, significantly more PMNs were
observed in the lungs of WT mice compared with MBL
null mice on day 1 (Figure 4B). This PMN influx was
caused by the viral infection because no PMN was
observed in the lungs of naïve MBL null and WT mice
(data not shown). We observed only MFs in the lung of
naïve MBL null and WT mice, and MFs were also the
predominant cell type at all time points during viral
infection (Figure 4C). These data suggested that MBL or
the effect of MBL/MASP activation was involved with
recruitment of WBCs, and in particular PMNs, into the
infected alveolar space during viral infection.
MFs of MBL null mice are prone to apoptosis
Viral infection is known to generate a large amount of
apoptotic cells [30]. Therefore, we looked for apoptotic
cells in the lungs of MBL null and WT mice on day 1
following IAV infection. Apoptotic MFs were signifi-
cantly increased in MBL null mice compared with WT
mice (Figure 4D). Although apoptotic PMNs were also
increased in MBL null mice compared with WT mice
this difference was not statistically significant (Figure
4D).
We subsequently assessed IAV infection-associated
cell death of MFs isolated from WT and MBL null
mice. Resident peritoneal MFs were prepared simulta-
neously and were infected with IAV. Unexpectedly,
MFs from MBL null mice had significantly higher
cell death compared with even IAV-infected WT MFs
(Figure 4E). Further, IAV infection increased cell death
of MBL null MFs (Figure 4E). In contrast, WT MF did
not show significantly increased cell death even after
IAV infection (Figure 4E).
Soluble factors in BALF following viral infection
We analyzed BALF for 62 soluble molecules during viral
infection using multiple factor assay kits. We focused on
day 1 post-viral infection because this time point
demonstrated a significant difference for viral titer and
WBC responses between WT and MBL null mice as we
Figure 4 White blood cells (WBC) and apoptosis susceptibility. A, Total WBC are expressed as cells per lung. B, PMN population as % of total
WBC. C, Macrophage population as % of total WBC. For all experiments A - C, two experiments were combined. Mice numbers used were 5 wild
type (WT) and 7 MBL null for day 1; 6 WT and 7 MBL null for day 4; and 8 WT and 7 MBL null for day 7. Data are expressed as mean ± SE. **,
p < 0.005 and ***, p < 0.001. D, Increased apoptotic macrophages (%) in BAL cells of MBL null mice on day 1 post-IAV infection. Experiments
were as in Figure 4A. Five wild type (WT) and 7 MBL null mice were used. Data are expressed as mean ± SE. **, p < 0.005. E, Viral infection
induced cell death. Macrophages (MF) from WT and MBL null mice were incubated with virus and cell death was expressed as % of WT MF
without viral infection. Assays were performed in triplicate. Data are expressed as mean ± SE. *, p < 0.05; **, p < 0.005; and ***, p < 0.0001.
Chang et al. BMC Immunology 2010, 11:64
http://www.biomedcentral.com/1471-2172/11/64
Page 7 of 12
described above. Ten molecules, CXCL16, MCP-1, MIP-
1g, PF4, sTNF RI, L-selectin, P-selectin, TIMP-1,
VCAM-1, and M-CSF increased to more than 10,000
units (Figure 5) (additional file 1). However, expression
level of these molecules was similar between WT and
MBL null mice except for platelet factor 4 (PF4) and
vascular cellular adhesion molecule-1 (VCAM-1), which
increased more than 2-fold in the BALF of MBL null
mice compared with WT mice. Similarly, 7 other mole-
cules were also increased in the BALF of MBL null
mice. These molecules included cytokines (IFN-g and
IL-1a); adhesion molecules (P-selectin); and other regu-
latory molecules (Axl tyrosine kinase, insulin-like growth
factor binding protein-6 (IGFBP-6), Leptin, and Leptin
receptor) (Figure 6). In contrast, only two molecules,
eotaxine (CCL 11) and IL-3 were increased more than
2-fold in WT mice compared with MBL null mice (Fig-
ure 6). These results suggested that MBL modulated
inflammation during IAV infection in the lung leading
to a numbers of changes in the balance of regulatory
molecules.
Discussion and Conclusion
Our results provide the first in vivo evidence that MBL
deficiency increases susceptibility to IAV infection.
Importantly, the increased infection susceptibility can be
improved with rhMBL, as administration of rhMBL to
MBL null mice reduced viral infection similar to WT
levels. This study also has revealed the presence of MBL
in the healthy resting lung. We used affinity purification
to isolate MBL from BALF. This procedure was clearly
more sensitive than ELISA, in which MBL was detected
only after infection [18]. In the previous study, MBL in
the BALF was measured by ELISA, which further dilutes
protein concentrations in addition to the initial dilution
from the fluid used to perform lung lavage [18]. We
confirmed that ELISA did not detect MBL in un-con-
centrated BALF that were also used in the previous
study [18]. These results suggest that MBL, a serum
protein, most likely leaks into the alveolar space and
that MBL also participates in innate immune protection
against infection in the lung.
This study demonstrates that MBL inhibits viral infec-
tion directly as well as indirectly with cooperation of
serum factors. These findings support previous studies
showing that MBL directly neutralizes and inhibits IAV
infection and that there are direct [10] and indirect anti-
viral activities, including involvement of complement
[31]. Of interest, we show that Phil82BS, which lacks
one glycosylation site from the parent strain Phil82, also
activates the lectin complement pathway and thrombin-
like activity despite reduced MBL binding. Robust com-
plement activation despite reduced binding of MBL to
Phil82BS could be explained by recent findings that the
lectin pathway activity is amplified by the alternative
pathway, suggesting that even a lower degree of binding
may be sufficient in inducing effective anti-viral activity
[32,33].
The sugar specificity of MBL-A and MBL-C is slightly
different and MBL-A is an acute phase protein while the
expression of MBL-C is not influenced to the same
extent by inflammatory stimuli [27]. We now show that
MBL-C is more effective in direct anti-viral activity than
MBL-A in vitro. This is the first observation demon-
strating a difference between MBL-A and MBL-C in
inhibiting a pathogen. This difference is diminished by
co-operation of serum factors, since MBL-C deficient
serum, which is MBL-A sufficient, is as effective as
MBL-A deficient serum (MBL-C sufficient) at neutraliz-
ing IAV. This cannot be attributed to an increase of
MBL-A in MBL-C null mice because our previous study
demonstrates that MBL-A in MBL-C null mice is simi-
lar to that in WT mice and vice versa [23]. Importantly,
these serum-facilitated anti-viral activities are initiated
by MBL because MBL null mice serum does not show
viral neutralizing activity even at high concentration.
MBL-ligand binding induces conformational changes
in MASPs, resulting in activated serine proteases. Sur-
prisingly, thrombin-like activity is mediated by MBL-C
whereas the lectin complement pathway is more effi-
ciently mediated by MBL-A (supporting our previous
findings [23]). These data suggest that direct anti-viral
activity of MBL-C correlates with thrombin-like activity.
Interestingly, human MBL is genetically homologous to
MBL-C and also mediates thrombin-like activity [13].
These findings raise the possibility that, in addition to
mediating complement activation, MBL may contribute
to host defense by activating coagulation. Hence, com-
plement and coagulation activity may be effective innate
immune mechanisms not only in primitive animals, like
the horseshoe crab, [14] but also in mammals.
Our study also demonstrates that MBL modulates cel-
lular responses, increasing recruitment of WBCs, and in
particular PMNs, which we have shown mediate viral
clearance [34], although the overall predominant cell
type is MF in both WT and MBL null mice. A marked
increase of apoptotic cells was observed in MBL null
mice during IAV infection. This result could be
explained, in part, by reduced clearance of apoptotic
cells, as MBL null mice have impaired apoptotic cell
removal [15]. An unexpected finding is that MFs of
MBL null mice seem to be susceptible to apoptosis once
these are isolated and placed in vitro.
Pathogenesis of IAV infection has been linked to poly-
merase basic (PB)1-F2, which induces apoptosis upon
infection [35], suggesting that viral infection induces
host cell apoptosis to minimize host cellular responses
to the virus. In this scenario, prevention of apoptosis is
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a host defense mechanism. Taken together, these obser-
vations suggest that immune cells of MBL deficient
hosts are more easily infected and more prone to apop-
tosis, and that impaired clearance of apoptotic cells
would further increase the burden of infection.
Multifactorial high throughput assays of BALF have
revealed that the lung of WT mice is relatively quiescent
compared with that of MBL null mice, because only two
molecules, IL-3 and eotaxin were increased following
IAV infection. Although IL-3, a mast cell growth factor,
Figure 5 Biological responses in bronchoalveolar fluid during IAV infection. Protein array experiments were performed on BALF from day 1
post-viral infection. BALF from 3 mice in each group were pooled. Arbitrary units of each molecule for WT and MBL null mice are shown. Data
are average of duplicates.
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has been linked to lung diseases in animal studies [36],
mast cells themselves have been known to play a role in
wound healing [37]. Eotaxin (CCL11) has been identified
in lung tissue repair as a chemo-attractant of airway
smooth muscle and as a lung fibroblast growth factor
[38]. These observations suggest that the lungs of WT
mice are in the wound-healing phase as early as on day
1 after IAV infection. In contrast, the lungs of MBL null
mice have increases of 9 molecules: Leptin, Leptin
receptor, IFN-g, IL-1a, PF4, IGFBP-6, P-selectin,
VCAM, and Axl tyrosine kinase. Surprisingly, all these
molecules have been associated with and/or attributed
to lung injuries [39-48], suggesting that MBL deficient
hosts may be prone to tissue damage from infection.
Moreover, these factors may also contribute to increased
susceptibility to apoptosis of MBL null macrophages, as
discussed above. Taken together, these observations sug-
gest that MBL plays a role in preventing tissue injury,
and further study is required to elucidate the details of
these processes.
It is important to note that even MBL deficient mice
cleared virus by day 4 in our study. The likelihood is that
lung-surfactant proteins are contributing to anti-viral
activity, as SP-A and SP-D are synthesized in the lung
and possess anti-viral activities, including neutralization,
opsonization and hemagglutination-inhibition of virus
[17]. Mice lacking SP-A or SP-D are susceptible to IAV
infection [17]. Although SP-A, SP-D and MBL belong to
the collectin family, the surfactant proteins do not acti-
vate complement, contrast to MBL [15]. Surfactant pro-
teins do not seem to form a complex with complement
activating serine proteases, such as MASPs, and most
likely do not activate coagulation. In contrast to these dif-
ferences, these three collectins do influence adaptive
immunity [49-51] although their influence and the details
of their actions against IAV are not well understood.
Taken together, these observations suggest that collectins
may function cooperatively together to eliminate virus.
Further studies are warranted to elucidate the details of
the interaction among these collectins.
In conclusion, our study demonstrates in vivo evidence
that MBL protects hosts from IAV infection and that MBL
may be a new useful adjunctive anti-IAV therapy. Anti-
IAV mechanisms include activation of the lectin comple-
ment pathway and of coagulation through a thrombin-like
activity, both of which are innate immune mechanisms.
Our investigation also suggests that MBL deficiency may
be a risk factor for IAV infection. Thus, MBL, as an ele-
ment of the innate immune system, plays an important
role in protecting and maintaining lung homeostasis.
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